RIPK1 and triple-negative breast carcinoma: Moreover, CRISPR/Cas9-mediated deletion of MIB1 and MIB2 also sensitized the triple-negative breast cancer cell line MDA-MB-231 to TNF/TAK1i in a RIPK1-dependent manner (Figure 2E).